Diabetic Foot Ulcers

Imaging Gallery

Click to expand

Click to expand

Click to expand

Imaging Gallery

Diabetic foot ulcers (DFUs) are chronic wounds occurring in individuals with diabetes mellitus, resulting from the interaction of neuropathy, peripheral arterial disease, and repetitive trauma. They represent the most common and costly complication of diabetes, with devastating consequences for patients and healthcare systems.

Epidemiology and Burden

Global Impact:

• Approximately 15% of individuals with diabetes will develop a foot ulcer during their lifetime
• Annual incidence: 2-4% among diabetic patients
• Prevalence in diabetic population: 4-10%
• 85% of diabetes-related amputations are preceded by foot ulcers

Outcomes and Prognosis:

• 5-24% of diabetic foot ulcers progress to amputation
• 50% of DFUs recur within 3 years despite initial healing
• 40% recur within 1 year
• 50% mortality at 5 years following major amputation (worse than most cancers)
• 30% mortality at 1 year following major amputation

Risk Factors

Major Risk Factors (evidence-based):

• Previous foot ulceration: strongest predictor (relative risk 12-36)
• Peripheral neuropathy: loss of protective sensation (10g monofilament)
• Peripheral arterial disease: ABI less than 0.9
• Foot deformity: claw toes, Charcot foot, hallux valgus
• High plantar pressure: greater than 600 kPa at forefoot
• Poor glycemic control: HbA1c greater than 8%
• Duration of diabetes: greater than 10 years
• Vision impairment: inability to self-inspect

Additional Risk Factors:

• Chronic kidney disease (dialysis patients 2-3x higher risk)
• Smoking (impairs wound healing)
• Limited joint mobility (especially ankle)
• Inappropriate footwear
• Male gender (1.6x higher risk)
• Low socioeconomic status

History

Key Questions:

• Duration of diabetes and glycemic control (HbA1c)
• Previous ulcers or amputations (strongest risk factor)
• Claudication, rest pain (vascular symptoms)
• Sensory symptoms: numbness, tingling, burning (neuropathy)
• Trauma or precipitating event (often forgotten by patient due to neuropathy)
• Footwear: what do they wear at home? (many patients wear inappropriate slippers)
• Self-care ability: can they see their feet? Can they reach to inspect?

Physical Examination

Vascular Assessment (The 5 P's):

• Pulses: dorsalis pedis, posterior tibial (compare sides)
• Pallor: elevation pallor test (Buerger test)
• Perfusion: capillary refill time (normal less than 3 seconds)
• Paresthesias: neuropathic symptoms
• Pain: rest pain suggests critical ischemia

Neurological Assessment:

• 10g monofilament testing: 9 sites on plantar foot (hallux, met 1-5, mid-arch, heel)
  • Loss of sensation at ANY site = loss of protective sensation
  • Sensitivity 90%, specificity 80% for ulcer risk
• Vibration perception: 128 Hz tuning fork at hallux IPJ
• Ankle reflexes: absent in peripheral neuropathy
• Pinprick: assesses small fiber function

Musculoskeletal Assessment:

• Foot deformities: claw toes, hallux valgus, Charcot neuroarthropathy
• Ankle range of motion: equinus (less than 10° dorsiflexion) increases forefoot pressure
• Muscle strength: intrinsic atrophy, inability to spread toes
• Gait analysis: observe pressure pattern

Ulcer Assessment:

• Location: plantar (neuropathic), margins/dorsum (ischemic), interdigital (mixed)
• Size: measure in cm² (length × width)
• Depth: probe to bone test
• Base: granulation tissue (red = healthy), slough (yellow), eschar (black)
• Edges: callused, undermined, macerated
• Surrounding skin: erythema (measure distance), warmth, edema
• Exudate: amount, color, odor

Probe-to-Bone Test:

• Sterile metal probe inserted into debrided ulcer
• Positive: hard, gritty resistance = bone felt
• Sensitivity 87%, specificity 83% for osteomyelitis
• Positive likelihood ratio 6.4 - if positive, assume osteomyelitis
• Negative likelihood ratio 0.15 - if negative, osteomyelitis unlikely (unless high clinical suspicion)

📊 Management Algorithm

Click to expand

Multidisciplinary Team Approach

Evidence: Multidisciplinary foot care teams reduce amputation rates by 49-85% compared to standard care.

Essential Team Members:

• Diabetologist or endocrinologist (glycemic control)
• Podiatrist (wound care, debridement, orthotics)
• Vascular surgeon (revascularization)
• Orthopaedic or plastic surgeon (reconstruction, amputation)
• Infectious disease specialist (complex infections, osteomyelitis)
• Orthotist (custom footwear, AFOs)
• Diabetes nurse educator (self-care, prevention)

The 5 Pillars of DFU Management

1. Offloading (CRITICAL) 2. Debridement 3. Infection Control 4. Vascular Assessment and Revascularization 5. Metabolic and Wound Environment Optimization

Total Contact Casting (Gold Standard)

Mechanism of Action:

• Redistributes pressure from ulcer site to entire plantar surface and lower leg
• Reduces peak plantar pressure by 80-90% at ulcer site
• Immobilizes ankle (reduces shear stress)
• Non-removable - ensures compliance (patients cannot cheat)

Technique:

• Apply minimal padding over ulcer and bony prominences
• Mold cast intimately to foot and leg (total contact)
• Extend to just below fibular head
• Heel rocker on bottom for gait
• Change weekly initially (edema reduction), then every 2 weeks

Outcomes:

• Healing rate: 85-95% at 12 weeks for Wagner 1-2 ulcers
• Healing time: 6-8 weeks average (vs 12-16 weeks in removable devices)
• Recurrence rate: 30-50% at 2 years (need long-term footwear)

Contraindications to TCC:

• Active infection (moderate or severe)
• Critical ischemia (ABI less than 0.5)
• Excessive edema (unstable limb volume)
• Non-compliant patient (fall risk)
• Suspected Charcot neuroarthropathy (acute phase)

Instant Total Contact Cast (iTCC Walker)

Alternative to TCC:

• Removable cam walker rendered non-removable with cohesive bandage or fiberglass
• Prefabricated device with custom foam padding
• Similar efficacy to TCC (75-90% healing) IF rendered non-removable
• Allows wound inspection without cast removal

Advantage: Can be temporarily removed for wound care by healthcare provider Disadvantage: If patient can remove it (non-compliance), efficacy drops to 30-50%

Other Offloading Devices

Key Principle: Non-removable greater than removable. Studies show patients wear removable devices only 20-30% of the time when alone at home, despite reporting "full compliance."

Surgical Offloading

Achilles Tendon Lengthening (ATL):

• Indication: Equinus contracture (ankle dorsiflexion less than 10°)
• Mechanism: reduces forefoot pressure by 25-30%
• Technique: percutaneous triple hemisection
• Outcomes: 60-80% reduction in recurrence vs standard care
• Risks: overlengthening → calcaneal ulcers

Metatarsal Head Resection:

• Indication: recurrent plantar ulcer under prominent met head
• Single met resection (usually met 2 or 3)
• Avoid multiple adjacent mets (transfer lesions)

Joint Arthroplasty (Met Head Resection with K-wire Fixation):

• Shortens metatarsal, elevates met head
• Healing rate: 80-90%

Sharp Debridement (Essential)

Rationale:

• Removes necrotic tissue, callus, and biofilm
• Converts chronic wound to acute wound (restarts healing cascade)
• Reduces bacterial burden by 90-99%
• Exposes healthy bleeding tissue

Technique:

• Weekly debridement until healed (at minimum)
• Use scalpel to remove all hyperkeratosis (callus) around wound edges
• Debride to healthy, bleeding tissue (Spongey-bleeding base indicates dermis)
• Saucerize edges (bevel wound edges to prevent undermining)
• Send tissue for culture (NOT swab)

Evidence: Weekly sharp debridement associated with 2-3x higher healing rates vs episodic debridement.

Wound Dressing Principles

Goal: Maintain moist wound environment (improves epithelialization by 50% vs dry wounds)

Dressing Selection by Wound Characteristics:

Dressing Change Frequency:

• Infected wounds: daily
• Clean granulating: every 3-7 days
• Goal: minimize wound disruption

Advanced Wound Therapies

Negative Pressure Wound Therapy (NPWT):

• Indications: post-surgical wounds, deep wounds after debridement
• Mechanism: removes exudate, reduces edema, promotes granulation
• Evidence: 30-50% faster healing vs standard dressings in diabetic wounds
• Contraindications: untreated osteomyelitis, exposed vessels, malignancy

Biological Agents:

• Platelet-derived growth factor (becaplermin): 50% increase in healing vs placebo (NNT = 7)
  • Apply daily after debridement
  • FDA-approved for diabetic neuropathic ulcers
• Living cell therapy: human fibroblast/keratinocyte sheets (Apligraf, Dermagraft)
  • Healing: 56% vs 38% with standard care at 12 weeks
  • Expensive (USD 1000-2500 per application)

Hyperbaric Oxygen Therapy (HBOT):

• Controversial evidence: some RCTs show benefit, others don't
• Mechanism: increases tissue oxygenation, enhances WBC function, angiogenesis
• Indications (if available): Wagner 3-4 with failed standard care
• Regimen: 90-120 minutes at 2.0-2.5 ATA, 30-40 sessions
• Cochrane review: insufficient evidence to recommend routinely

IDSA/IWGDF Infection Criteria

Diagnosis of Infection (NOT just colonization):

• Purulence (pus), OR
• 2 or more inflammatory signs:
  • Local warmth
  • Erythema (greater than 2 cm from wound edge = moderate infection)
  • Lymphangitis
  • Edema
  • Pain or tenderness (unusual in neuropathic patients - ominous if present)

Severity Grading:

Antibiotic Therapy

Principles:

• Treat infection, NOT colonization - all chronic wounds are colonized
• Empiric therapy based on severity and previous cultures
• Narrow to culture results after 48-72 hours
• Duration: 1-2 weeks for soft tissue; 4-6 weeks for osteomyelitis

Empiric Regimens (IDSA Guidelines):

Mild Infection (outpatient, oral):

• Cephalexin 500mg QID, OR
• Amoxicillin-clavulanate 875mg BID, OR
• Clindamycin 300mg TID (if penicillin allergy)
• Duration: 1-2 weeks

Moderate Infection (inpatient or close outpatient):

• Ampicillin-sulbactam 3g IV Q6H, OR
• Ceftriaxone 2g IV daily PLUS metronidazole 500mg IV Q8H, OR
• Ertapenem 1g IV daily (if MRSA risk, add vancomycin)

Severe Infection (inpatient, broad-spectrum):

• Vancomycin 15mg/kg IV Q12H (trough 15-20) PLUS
  • Piperacillin-tazobactam 4.5g IV Q6H, OR
  • Meropenem 1g IV Q8H
• Consider antifungal if prolonged antibiotics or immunosuppressed

MRSA Coverage (add if risk factors: previous MRSA, healthcare exposure, failed cephalosporin):

• Vancomycin, OR
• Linezolid 600mg PO/IV BID, OR
• Daptomycin 6mg/kg IV daily

Osteomyelitis Management

Diagnosis:

• Probe-to-bone positive (LR+ 6.4)
• MRI: bone marrow edema + cortical destruction
• Bone biopsy (gold standard): histology + culture

Treatment Options:

1. Surgical Debridement + Antibiotics (preferred):

• Remove all infected, necrotic bone until bleeding viable bone
• Send bone for culture and histology
• IV antibiotics for 4-6 weeks based on bone culture
• Cure rate: 60-80% for non-heel, 40-60% for heel

2. Antibiotics Alone (selected cases):

• Indications: poor surgical candidate, patient refuses, minor bone involvement
• 6-12 weeks IV or highly bioavailable oral (fluoroquinolone, linezolid)
• Cure rate: 60-70% (similar to surgery in some studies)
• Requires close follow-up

3. Amputation:

• Indications: extensive bone destruction, failed conservative treatment, limb not salvageable
• May be curative if removes all infected tissue

Definition and Pathophysiology

Charcot neuroarthropathy (Charcot foot) is a progressive destructive arthropathy of the foot and ankle in patients with peripheral neuropathy, resulting in bone and joint destruction, fractures, and deformity.

Incidence: 0.1-0.4% of diabetics; up to 30% in high-risk diabetic populations

Pathophysiology (two theories):

• Neurovascular theory: autonomic neuropathy → increased blood flow → bone resorption
• Neurotraumatic theory: loss of protective sensation → repetitive microtrauma → fractures

Eichenholtz Classification (Stages)

Stage 0 (Prodromal):

• Warm, swollen foot
• NO X-ray changes yet
• Mimics cellulitis or DVT
• Critical to diagnose - treat now to prevent deformity

Stage 1 (Development/Fragmentation):

• X-ray: fractures, fragmentation, joint dislocation
• Clinically: warm, swollen, erythematous
• Most important stage to immobilize

Stage 2 (Coalescence):

• X-ray: absorption of debris, early healing
• Clinically: edema decreases, warmth decreases
• Continue immobilization

Stage 3 (Reconstruction/Consolidation):

• X-ray: bony remodeling, sclerosis, deformity is now fixed
• Clinically: cool, stable
• Transition to protective footwear/AFO

Clinical Patterns

Type 1 (Midfoot - 60%):

• Tarsometatarsal joints (Lisfranc)
• Rocker-bottom deformity
• High risk of plantar ulceration at apex

Type 2 (Hindfoot - 30%):

• Subtalar, talonavicular, calcaneocuboid joints
• Valgus or varus deformity

Type 3a (Ankle - 10%):

• Tibiotalar joint
• Unstable, high amputation risk

Type 3b (Calcaneus):

• Calcaneal fracture
• Loss of heel height

Management

Acute Phase (Stage 0-1):

• Non-weight bearing in total contact cast
• Cast changes every 1-2 weeks (monitor for progression)
• Serial X-rays to monitor healing
• Continue until: edema resolved, temperature difference less than 2°C compared to contralateral
• Duration: typically 3-6 months minimum

Subacute/Chronic (Stage 2-3):

• Gradual transition to weight-bearing in CROW walker (Charcot Restraint Orthotic Walker)
• Custom AFO or CROW boot for long-term use
• Extra-depth shoes with custom orthotics

Surgical Indications:

• Recurrent ulceration despite bracing
• Severe instability preventing bracing
• Techniques: exostectomy, osteotomy, arthrodesis (fusion)
• High complication rate (nonunion, infection, Charcot recurrence)

Risk Stratification and Surveillance

IWGDF Risk Categories and Surveillance Frequency:

• Category 0 (no neuropathy): annual screening
• Category 1 (neuropathy alone): 6-12 month screening
• Category 2 (neuropathy + PAD or deformity): 3-6 month screening
• Category 3 (previous ulcer or amputation): 1-3 month screening

Patient Education (Self-Care)

Daily Foot Inspection:

• Look for blisters, cuts, cracks, redness
• Use mirror if cannot see bottom of foot
• Check between toes
• If vision impaired, have caregiver inspect

Daily Foot Care:

• Wash with lukewarm water (test with elbow, not foot)
• Dry thoroughly, especially between toes
• Apply moisturizer (but NOT between toes)
• Check shoes for foreign objects before wearing

Nail Care:

• Cut toenails straight across (not rounded)
• File edges smooth
• If cannot reach or see, have podiatrist cut nails

What NOT to Do:

• Do NOT walk barefoot (inside or outside)
• Do NOT use heating pads or hot water bottles on feet
• Do NOT try to remove calluses or corns themselves (risk of injury)
• Do NOT smoke (impairs healing)

Footwear Prescription

Therapeutic Footwear:

• Extra-depth shoes (1/2 inch extra toe box depth)
• Custom orthotics with accommodative padding
• Rocker-sole to reduce forefoot pressure
• Medicare covers for diabetics with neuropathy or deformity

Post-Ulcer Footwear:

• Continue protective footwear lifelong
• Replace every 6-12 months (breaks down with use)
• Replace orthotics annually

Glycemic Control

Evidence: Each 1% reduction in HbA1c associated with 25% reduction in microvascular complications (including neuropathy)

Target: HbA1c less than 7% (individualize based on patient factors)

Multidisciplinary Prevention Programs

Components of Successful Programs:

• Regular screening (based on risk category)
• Patient education (structured programs)
• Therapeutic footwear provision
• Podiatry for nail and callus care
• Prompt treatment of pre-ulcerative lesions

Evidence: Comprehensive prevention programs reduce:

• Ulcer incidence by 50-60%
• Amputation rates by 49-85%
• Recurrent ulcers by 35-50%

PBS and Healthcare Considerations

Pharmaceutical Benefits Scheme (PBS):

• Advanced wound care products available under PBS for diabetic foot ulcers meeting criteria
• Becaplermin (Regranex) may be available through special access scheme
• Antibiotic coverage for diabetic foot infections under standard PBS

Public System Coverage:

• Podiatry services for diabetic patients with active ulcers or high-risk foot
• Multidisciplinary care plans (GP Management Plans, Team Care Arrangements)
• Wound care and debridement procedures covered
• Vascular imaging and intervention fully funded

National Diabetes Services Scheme (NDSS)

Provides subsidized:

• Blood glucose monitoring
• Insulin delivery devices
• Educational resources for foot care

Australian Clinical Practice

High-risk foot services across major metropolitan hospitals include multidisciplinary teams consistent with international guidelines. Regional and remote areas may require telehealth consultation with tertiary centers.